Globus Medical has completed its acquisition of Nevro, a company delivering solutions for treatment of chronic pain.

Acquiring Nevro unlocks a $2.5 billion market opportunity in the musculoskeletal market for Globus. The move positions it to potentially alter the standard of care in the neuromodulation space and beyond.

Nevro’s HFX spinal cord stimulation (SCS) platform includes the Senza SCS system and support services to treat chronic pain of the trunk and painful diabetic neuropathy. The company also offers minimally invasive treatment options for patients with chronic sacroiliac (SI) joint pain.

Globus acquired all shares of Nevro for $5.85 per share, in cash. The transaction, which was first announced in February, represents a total equity value of about $250 million.

“We are excited to begin the journey of accelerating market penetration of Nevro’s differentiated high-frequency technology and bringing a much-needed treatment option to patients suffering from chronic pain,” said Dan Scavilla, president and CEO of Globus Medical.

In November 2024, the company launched the ExcelsiusHub navigation system, which joins the expansive ecosystem of Excelsius technologies and is designed to elevate the standard for freehand navigation. This system includes safety features that pair navigational accuracy with features designed to enhance patient safety, such as patient array shift tracking and navigation of the DuraPro Oscillating System.